ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
28/09/26	$0.000100	+9,900.00%	485
25/09/26	$0.000001	-90.00%	100
24/09/26	$0.000010	-90.00%	280
23/09/26	$0.000100	-0.99%	330
22/09/26	$0.000101	+1.00%	304

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets 19:30:21 28/09/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		0.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.61M 3.41M 3.09M 5.81M 394M 5.84M 40.84M 15.77M 201M 15.4M 15.06M 646M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.14M -1.08M -977K -1.84M -124M -1.85M -12.9M -4.98M -63.47M -4.86M -4.76M -204M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news: ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Price Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		0.4
5 years	0		3.17
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	+9,900.00%	0.00%	0.00%	-99.89%	11.72K
WUXI APPTEC CO., LTD.	-0.37%	-3.67%	+57.21%	+87.75%	71.81B
ARGENX SE	-0.07%	-2.70%	+37.74%	+86.90%	60.06B
WUXI BIOLOGICS (CAYMAN) INC.	0.00%	+1.23%	+34.60%	+16.76%	27.93B
INSMED INCORPORATED	-0.14%	-2.75%	-14.13%	+356.79%	25.7B
BIONTECH SE	+0.57%	+1.10%	+1.02%	-2.89%	24.89B
GENMAB A/S	+1.10%	+1.86%	+25.07%	-7.59%	20.92B
PHARMAESSENTIA CORPORATION	-1.70%	+0.43%	+150.24%	+323.16%	15.04B
EXELIXIS, INC.	+0.36%	+2.01%	+49.51%	+160.70%	14.46B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+4.26%	-3.14%	-4.20%	+519.84%	13.87B
Average	+990.39%	-1.37%	+33.71%	+144.15%	27.47B
Weighted average by Cap.	+0.13%	-1.91%	+38.03%	+128.59%

	2021	2022
Net sales	-	19.64M 17.27M 16.33M 14.81M 27.82M 1.88B 27.98M 196M 75.52M 962M 73.73M 72.13M 3.09B
Net income	-58.38M -51.34M -48.55M -44.04M -82.7M -5.6B -83.18M -581M -225M -2.86B -219M -214M -9.19B	-29.88M -26.28M -24.85M -22.54M -42.33M -2.87B -42.57M -298M -115M -1.46B -112M -110M -4.7B
Net Debt	-28.08M -24.69M -23.35M -21.18M -39.77M -2.69B -40M -280M -108M -1.38B -105M -103M -4.42B	-5.4M -4.75M -4.49M -4.07M -7.65M -518M -7.69M -53.74M -20.76M -264M -20.26M -19.82M -850M

1 day	+9,900.00%
6 months	+900.00%